Featured Articles

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for cobas MPXV for use on the cobas 6800/8800 Systems. The test is a real time…
Read More...

Ferring Pharmaceuticals and Gubra entered into a collaboration agreement to further develop and characterize preclinical animal models of inflammatory bowel disease (IBD). The…
Read More...

Bayer announced the acquisition of German biotech start-up Targenomix. The spin-off of the Max Planck Institute for Molecular Plant Physiology (MPI MPP) uses novel systems biology and…
Read More...

AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S ), has been granted full Marketing Authorisation (MA) in the European Union (EU). Vaxzevria was originally granted a conditional…
Read More...

Seres Therapeutics, Inc. announced the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for investigational oral microbiome…
Read More...

Bayer Inc. announced that Health Canada approved finerenone, under the brand name KERENDIA, as an adjunct to standard of care therapy in adults with chronic kidney disease (CKD) and…
Read More...

WuXi Biologics and Toregem BioPharma announced that they have signed a Memorandum of Understanding (MOU) to form a strategic partnership in the development of TRG035, a monoclonal…
Read More...

CytoReason announced an extension of its multi-year partnership with Pfizer to use CytoReason’s artificial intelligence technology for Pfizer’s drug development programs. Under the…
Read More...

Gilead Sciences, Inc. announced updates to the World Health Organization’s (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury (remdesivir) for…
Read More...

Mallinckrodt plc announced that the U.S. Food and Drug Administration (FDA) approved Terlivaz (terlipressin) for injection. Terlivaz is the first and only FDA-approved product indicated…
Read More...

Gatehouse Bio, a pioneer in small RNA therapeutics, and AstraZeneca, a global, science-led biopharmaceutical company, are advancing their partnership, to create RNA therapeutics for the…
Read More...

Pfizer Inc. announced that its investigational Group B Streptococcus (GBS) vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the U.S. Food and Drug…
Read More...

Boehringer Ingelheim announced the U.S. Food and Drug Administration has approved SPEVIGO, the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults.…
Read More...

Novo Nordisk and Forma Therapeutics, Holdings Inc. announced that they have entered into a definitive agreement under which Novo Nordisk will acquire Forma Therapeutics for USD 20 per…
Read More...

Novartis announced its intention to separate Sandoz, its generics and biosimilars division into a new publicly traded standalone company, by way of a 100% spin-off. The spin-off aims…
Read More...

AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic non-small cell lung…
Read More...

Gilead Sciences, Inc. and MiroBio announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MiroBio for approximately $405 million in…
Read More...

Pfizer Inc., MorphoSys U.S. Inc., a fully owned subsidiary of MorphoSys AG, and Incyte (NASDAQ:INCY) today announced a clinical trial collaboration and supply agreement to investigate…
Read More...

GSK plc announced that it has entered into a definitive agreement to acquire Affinivax, Inc. (Affinivax), a clinical-stage biopharmaceutical company based in Cambridge, Boston,…
Read More...